Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions

被引：0
|
作者：
Zeidan, Amer M. [1 ,2 ]
Zhu, Weiwei [2 ]
Wang, Rong [3 ,4 ]
Stahl, Maximilian [1 ,2 ]
Huntington, Scott F. [3 ,5 ]
Giri, Smith [3 ,6 ]
Podoltsev, Nikolai A. [1 ,2 ]
Gore, Steven D. [1 ,3 ]
Ma, Xiaomei [2 ,4 ]
Davidoff, Amy J. [3 ,7 ]
机构：
[1] Yale Sch Med, Sect Hematol, Dept Internal Med, New Haven, CT USA
[2] Yale Sch Med, Yale Canc Outcomes Publ Policy & Effectiveness Re, New Haven, CT USA
[3] Yale Univ, Sch Med, Yale Canc Outcomes Publ Policy & Effectiveness Re, New Haven, CT USA
[4] Yale Univ, Yale Sch Publ Hlth, Dept Chron Dis, New Haven, CT USA
[5] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06510 USA
[6] Yale Univ, Sch Med, Sect Hematol, New Haven, CT USA
[7] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-116497
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
838
引用
收藏
页数：3
相关论文
共 49 条
  • [41] Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).
    Garcia-Manero, Guillermo
    Platzbecker, Uwe
    Santini, Valeria
    Zeidan, Amer Methqal
    Fenaux, Pierre
    Komrokji, Rami S.
    Shortt, Jake
    Valcarcel, David
    Jonasova, Anna
    Dimicoli-Salazar, Sophie
    Tiong, Ing Soo
    Lin, Chien-Chin
    Li, Jiahui
    Kreitz, Sandra
    Pozharskaya, Veronika
    Shetty, Jeevan K.
    Degulys, Andrius
    Finelli, Carlo
    Cluzeau, Thomas
    Della Porta, Matteo Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] Continuous Transfusion Independence With Imetelstat in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase III
    Platzbecker, Uwe
    Santini, Valeria
    Fenaux, Pierre
    Sekeres, Mikkael
    Savona, Michael
    Madanat, Yazan
    Diez-Campelo, Maria
    Valcarcel-Ferreiras, David
    Illmer, Thomas
    Jonasova, Anna
    Belohlavkova, Petra
    Sherman, Laurie
    Berry, Tymara
    Dougherty, Souria
    Shah, Sheetal
    Xia, Qi
    Peng, Lixian
    Sun, Libo
    Wang, Ying
    Huang, Fei
    Ikin, Annat
    Navada, Shyamala
    Feller, Faye
    Komrokji, Rami
    Zeidan, Amer
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S371 - S371
  • [43] A PHASE 3 STUDY OF LENALIDOMIDE VERSUS PLACEBO IN RBC TRANSFUSION-DEPENDENT (TD) PATIENTS WITH LOWER-RISK MDS WITHOUT DEL(5Q) UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
    Santini, V.
    Almeida, A.
    Giagounidis, A.
    Groepper, S.
    Jonasova, A.
    Vey, N.
    Mufti, G. J.
    Buckstein, R.
    Mittelman, M.
    Platzbecker, U.
    Shpilberg, O.
    Ram, R.
    del Canizo, C.
    Gattermann, N.
    Ozawa, K.
    Risueno, A.
    MacBeth, K. J.
    Zhong, J.
    Seguy, F.
    Hoenekopp, A.
    Beach, C. L.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2015, 39 : S60 - S61
  • [44] Imetelstat Treatment Leads to Durable Transfusion Independence in RBC Transfusion-Dependent, Non-Del(5q) Lower-Risk MDS Relapsed/Refractory to a Erythropoiesis-Stimulating Agent Who Are Lenalidomide- and HMA-Naive
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 12 - 13
  • [45] Luspatercept significantly reduces red blood cell transfusion burden, regardless of gene mutation frequency, spectrum, and prognostic significance, among patients with lower-risk myelodysplastic syndromes enrolled in the MEDALIST trial
    Mufti, G. J.
    Vyas, P.
    Garcia-Manero, G.
    Buckstein, R.
    Santini, V.
    Diez-Campelo, M.
    Finelli, C.
    Ilhan, O.
    Sekeres, M. A.
    Komrokji, R. S.
    Zeidan, A. M.
    Verma, A.
    Dunshee, R.
    Laadem, A.
    Linde, P. G.
    List, A. F.
    Fenaux, P.
    Platzbecker, U.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 149 - 150
  • [46] Disease Modifying Activity of Imetelstat in Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase
    Santini, Valeria
    Platzbecker, Uwe
    Fenaux, Pierre
    Sekeres, Mikkael
    Savona, Michael
    Madanat, Yazan
    Diez-Campelo, Maria
    Valcarcel-Ferreiras, David
    Illmer, Thomas
    Jonasova, Anna
    Belohlavkova, Petra
    Sherman, Laurie
    Berry, Tymara
    Dougherty, Souria
    Shah, Sheetal
    Xia, Qi
    Peng, Lixian
    Sun, Libo
    Wan, Ying
    Huang, Fei
    Ikin, Annat
    Navada, Shyamala
    Feller, Faye
    Zeidan, Amer
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S373 - S374
  • [47] Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005)
    Santini, Valeria
    Almeida, Antonio
    Giagounidis, Aristoteles
    Groepper, Stephanie
    Jonasova, Anna
    Vey, Norbert
    Mufti, Ghulam J.
    Buckstein, Rena
    Mittelman, Moshe
    Platzbecker, Uwe
    Shpilberg, Ofer
    Ram, Ron
    del Canizo, Consuelo
    Gattermann, Norbert
    Ozawa, Keiya
    Zhong, Jim
    Seguy, Francis
    Hoenekopp, Albert
    Beach, C. L.
    Fenaux, Pierre
    BLOOD, 2014, 124 (21)
  • [48] A phase 3, randomized, double-blind study of luspatercept (ACE-536) in patients (pts) with Revised International Prognostic Scoring System (IPSS-R) very low- to intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell (RBC) transfusions: The MEDALIST trial.
    Platzbecker, Uwe
    Komrokji, Rami S.
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    Mufti, Ghulam J.
    Sekeres, Mikkael A.
    Zhang, Jennie
    Benzohra, Aziz
    Laadem, Abderrahmane
    Vo, Bond
    Attie, Kenneth M.
    List, Alan F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes ( MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions
    Fenaux, Pierre
    Mufti, Ghulam J.
    Buckstein, Rena
    Santini, Valeria
    Diez-Campelo, Maria
    Finelli, Carlo
    Cazzola, Mario
    Ilhan, Osman
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    List, Alan F.
    Zeidan, Amer M.
    Verma, Amit
    Laadem, Abderrahmane
    Ito, Rodrigo
    Zhang, Jennie
    Rampersad, Anita
    Sinsimer, Daniel
    Linde, Peter G.
    Garcia-Manero, Guillermo
    Platzbecker, Uwe
    BLOOD, 2019, 134
12345